Company News

Focusing on IVD sector, we provide trustworthy quality products and professional services to domestic and international customers

Publication of the First English Academic Article on Clinical Application of MMP3

Published on: December 20, 2017

Driven by the Strategic Marketing Department of Runda Medical, the world’s first academic article on clinical application of MMP3 was published in “Arthritis Research & Therapy”, and scored no less than 4.2 points. The first author of this article is Dr. Zhou Ling, Attending Doctor of Rheumatology Department of Shanghai Changzheng Hospital, and the corresponding author is Dr. Xu Huji, Chief Physician of rheumatology department of Shanghai Changzheng Hospital.

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by symmetry and multiple joints inflammation. The major affected site is synovial membranes and Matrix metalloproteinase 3 (MMP3) can be an important predictor of RA disease activity, as well as the indicator of synovial damage and prognosis in patients with rheumatoid arthritis. The detection of MMP3 has a wide range of clinical applications in Japan.

The MMP3 reagent is independently developed by Shanghai Huachen Biological Reagent Co., Ltd., a wholly-owned subsidiary of Runda Medical. This product is under the process of registration.